Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: KalVista Pharma

Market Cap 1.44B 1.24B 1.14B 1.07B 2.02B 136B 2.03B 13.51B 5.26B 66.58B 5.4B 5.28B 230B P/E 2026 *
-32.3x
P/E 2027 * 15.8x
Enterprise Value 1.3B 1.12B 1.03B 968M 1.82B 122B 1.83B 12.18B 4.74B 60.04B 4.86B 4.76B 208B EV / Sales 2026 *
5.94x
EV / Sales 2027 * 3.48x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+0.04%
1 week+0.04%
Current month+0.48%
1 month+1.01%
3 months+60.52%
6 months+69.81%
Current year+67.18%
1 month 26.71
Extreme 26.71
27
Current year 14.22
Extreme 14.22
27
1 year 9.83
Extreme 9.83
27
3 years 7.21
Extreme 7.21
27
5 years 4.12
Extreme 4.12
30.14
10 years 0
Extreme 0
45
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/11/2016
Chief Executive Officer 61 06/03/2024
President - 11/06/2026
Director TitleAgeSince
Chairman - 11/06/2026
Date Insider Type Main position Quantity % Market Cap.
06-11Issuer sale

Executive/Senior Manager

-361,791 0.7158%
06-11Issuer sale

Director

-45,000 0.0890%
06-11Issuer sale

Executive/Senior Manager

-640,088 1.2663%

Financials

2026 *2027 *
Net sales 218M 188M 173M 163M 306M 20.58B 309M 2.05B 798M 10.1B 819M 801M 34.95B 351M 302M 278M 262M 492M 33.09B 496M 3.3B 1.28B 16.24B 1.32B 1.29B 56.17B
Net income -71.87M -62M -57M -53.65M -101M -6.78B -102M -676M -263M -3.33B -270M -264M -11.52B 36.3M 31.32M 28.79M 27.1M 50.92M 3.43B 51.35M 341M 133M 1.68B 136M 133M 5.82B
Net Debt -141M -122M -112M -105M -198M -13.34B -200M -1.33B -517M -6.54B -530M -519M -22.64B -216M -187M -172M -161M -303M -20.41B -306M -2.03B -792M -10.02B -812M -794M -34.66B
Logo KalVista Pharma
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
Employees
275
Sector
-
Date Price Change Volume
10/06/26 27.00 $ +0.04% 4,272,770
09/06/26 26.99 $ 0.00% 1,537,918
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. KALV Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!